Haemonetics (NYSE:HAE) Posts Quarterly Earnings Results, Beats Estimates By $0.06 EPS

Haemonetics (NYSE:HAE) issued its earnings results on Thursday. The medical instruments supplier reported $1.14 EPS for the quarter, topping the consensus estimate of $1.08 by $0.06, FiscalAI reports. Haemonetics had a net margin of 7.12% and a return on equity of 27.55%. The company had revenue of $339.38 million for the quarter, compared to the consensus estimate of $327.86 million. During the same period in the previous year, the firm earned $1.10 earnings per share. The firm’s revenue for the quarter was up 5.5% on a year-over-year basis.

Here are the key takeaways from Haemonetics’ conference call:

• Haemonetics raised fiscal 2027 guidance, now expecting reported revenue growth of 5%–8% and organic growth of 4%–7%, following first-quarter revenue growth of 6% and adjusted EPS growth of 4% to $1.14.
• Plasma revenue increased 8% organically, supported by double-digit disposable growth, share gains, strong collection volumes, and the early rollout of Persona PLUS, which is delivering more than 5% yield improvements for early adopters.
• Interventional technologies returned to growth, led by low-double-digit vascular closure growth. The VASCADE MVP XL indication expansion, new clinical evidence, and stronger sales execution are supporting account wins and increased utilization in PFA and other large-bore procedures.
• Cash generation was strong, with operating cash flow tripling year over year to $52 million and trailing-12-month free-cash-flow conversion reaching 106% of adjusted net income. The company used cash to repay $100 million of revolver debt and retains flexibility for growth investments and opportunistic share repurchases.
• External cost pressures remain a headwind, including tariffs, transportation and oil-related costs, material inflation, and higher personnel expenses. Slower cell-salvage capital upgrades and weakness in OEM and esophageal-cooling businesses also weighed on parts of MedSurg and interventional technologies.

Haemonetics Trading Up 2.9%

Shares of HAE traded up $2.48 during trading hours on Friday, reaching $87.50. 657,064 shares of the company traded hands, compared to its average volume of 737,142. Haemonetics has a 12 month low of $47.31 and a 12 month high of $88.58. The company has a quick ratio of 1.87, a current ratio of 3.08 and a debt-to-equity ratio of 1.40. The company’s fifty day moving average price is $76.98 and its two-hundred day moving average price is $66.52. The company has a market capitalization of $3.98 billion, a price-to-earnings ratio of 42.89, a price-to-earnings-growth ratio of 1.71 and a beta of 0.52.

Institutional Trading of Haemonetics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. AQR Capital Management LLC grew its holdings in Haemonetics by 372.8% in the third quarter. AQR Capital Management LLC now owns 2,128,878 shares of the medical instruments supplier’s stock worth $102,814,000 after purchasing an additional 1,678,630 shares during the period. Millennium Management LLC lifted its holdings in shares of Haemonetics by 4,296.3% during the third quarter. Millennium Management LLC now owns 773,179 shares of the medical instruments supplier’s stock valued at $37,685,000 after purchasing an additional 755,592 shares during the last quarter. Balyasny Asset Management L.P. purchased a new position in shares of Haemonetics during the third quarter valued at approximately $15,703,000. Qube Research & Technologies Ltd bought a new stake in shares of Haemonetics in the 3rd quarter worth approximately $13,178,000. Finally, Janus Henderson Group PLC boosted its position in shares of Haemonetics by 731.5% in the 4th quarter. Janus Henderson Group PLC now owns 186,719 shares of the medical instruments supplier’s stock worth $14,965,000 after purchasing an additional 164,263 shares in the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Haemonetics

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Haemonetics reported fiscal Q1 2027 earnings of $1.14 per share, exceeding the $1.07–$1.08 consensus range. Revenue rose 5.5% year over year to $339.4 million, also comfortably ahead of expectations near $327.9 million. The earnings and sales beats indicate continued operating momentum. Haemonetics Tops Q1 Earnings and Revenue Estimates
• Positive Sentiment: Management raised its fiscal 2027 outlook and now expects reported revenue growth of approximately 5% to 8%. The improved forecast, following a strong first quarter, supports the view that demand and execution are better than previously anticipated. Haemonetics Raises Fiscal 2027 Revenue Guidance
• Positive Sentiment: BTIG Research raised its Haemonetics price target from $84 to $96 and maintained a “buy” rating, implying additional upside based on the company’s earnings performance and outlook. BTIG Raises Haemonetics Price Target
• Neutral Sentiment: Citigroup lifted its price target from $79 to $92, while retaining a “neutral” rating. The higher target reflects improved estimates but suggests limited conviction at the current valuation. Citigroup Analyst Update
• Neutral Sentiment: JPMorgan raised its target from $62 to $86 but maintained a “neutral” rating. The revised target remains slightly below the recent trading level, signaling that valuation may constrain further gains despite the improved outlook. JPMorgan Analyst Update

Analyst Upgrades and Downgrades

HAE has been the topic of a number of recent analyst reports. Bank of America raised shares of Haemonetics from a “neutral” rating to a “buy” rating and raised their price target for the stock from $72.00 to $80.00 in a report on Friday, May 22nd. Robert W. Baird set a $96.00 price objective on shares of Haemonetics in a research note on Friday. Weiss Ratings upgraded shares of Haemonetics from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, June 25th. Barrington Research set a $95.00 target price on Haemonetics in a research note on Friday. Finally, Citigroup boosted their price target on Haemonetics from $79.00 to $92.00 and gave the company a “neutral” rating in a report on Friday. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, Haemonetics presently has a consensus rating of “Moderate Buy” and an average target price of $90.89.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.